Welcome to our dedicated page for BIONTECH SEC filings (Ticker: BNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioNTech SE filings document the disclosures of a foreign private issuer that reports to the SEC primarily through Form 6-K current reports and annual reports on Form 20-F. The records cover interim condensed consolidated financial statements, operating and financial reviews, corporate updates, and exhibit filings related to press releases and investor presentations.
BioNTech’s filings also describe ADS-related capital actions, including repurchase program disclosures for American Depositary Shares representing ordinary shares. Other recurring subjects include annual general meeting invitations and shareholder voting mechanics, governance matters, clinical and regulatory updates for oncology programs, COVID-19 vaccine activity, collaboration-related pipeline information, and material-event disclosures affecting capital allocation and corporate strategy.
BioNTech SE has launched a share buyback program for its American Depositary Shares (ADSs) with a total value of up to USD 1.0 billion. The program covers ADSs listed on the U.S. Nasdaq Global Select Market and runs from June 8, 2026 through May 6, 2027.
The company expects to use repurchased ADSs to satisfy obligations in the ordinary course of business, enhance capital efficiency and maintain financial flexibility. The program is carried out under an AGM authorization that permits acquiring up to 10% of share capital, capped at 24.9 million shares, and is structured to comply with EU regulations and U.S. Rules 10b-18 and 10b5-1.
BioNTech and Bristol Myers Squibb reported interim Phase 2 data from the global ROSETTA Lung-02 trial of the investigational bispecific immunomodulator pumitamig plus chemotherapy in previously untreated advanced non-small cell lung cancer.
Among 40 response-evaluable patients with a median follow-up of 9.0 months, pumitamig plus chemotherapy achieved confirmed objective response rates of 57.1% in non-squamous and 68.4% in squamous disease, with a disease control rate of 100%. At the lower evaluated dose, response rates rose to 63.6% and 72.7% respectively, and response rates were high across PD-L1 expression levels, including 100% in patients with PD-L1 TPS ≥ 50%. Safety was described as manageable, with grade ≥ 3 treatment-related adverse events in 48.8% of patients, pumitamig-related in 23.3%, leading to discontinuation in 9.3%. Pumitamig is moving into an extensive Phase 3 program in NSCLC and other tumor types.
BioNTech SE is using the 2026 ASCO Annual Meeting to showcase progress in its late-stage oncology pipeline. The company will present new clinical data and trial updates for key assets, including the bispecific immunomodulator pumitamig and the CTLA-4 antibody gotistobart, plus several antibody-drug conjugate programs.
Interim Phase 2 data from the global Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer showed encouraging anti-tumor activity for pumitamig plus chemotherapy and are informing the ongoing pivotal Phase 3 part. Phase 2 data for gotistobart in heavily pre-treated, platinum-resistant ovarian cancer showed durable anti-tumor activity and clinically meaningful overall survival with a manageable safety profile.
Overall, BioNTech highlights more than 25 Phase 2 and Phase 3 trials, including 13 pivotal studies and multiple novel-novel combination trials across major tumor types, underscoring a broad late-stage oncology strategy spanning immunomodulators, ADCs, and mRNA cancer immunotherapies.
BioNTech SE reported that shareholders approved all agenda items at the 2026 Annual General Meeting, with around 92% of share capital represented. The Supervisory Board was expanded from six to eight members and two new oncology-focused experts, Prof. Iris Löw‑Friedrich and Dr. Susanne Schaffert, were elected alongside extensions for three existing members.
Management emphasized a strategy pivot toward the growing late‑stage oncology pipeline while maintaining infectious disease programs. For 2025, BioNTech posted IFRS revenues of €2,870 million, above its €2,600–2,800 million guidance range. In Q1 2026, revenues were €118 million and cash, cash equivalents and security investments totaled €16.8 billion, supporting continued R&D investment.
The company reaffirmed 2026 non‑IFRS revenue guidance of €2,000–2,300 million, with adjusted R&D expenses of €2,200–2,500 million and adjusted SG&A expenses of €700–800 million. BioNTech highlighted a $3.5 billion up‑front and non‑contingent payment and up to $7.6 billion in milestones from its BMS partnership around pumitamig, plans for up to $1.0 billion in share repurchases over twelve months, and manufacturing consolidation measures expected to reach about €500 million in recurring annual savings by 2029.
BioNTech SE reports beneficial ownership disclosures by Medine GmbH and Prof. Ugur Sahin, M.D. The statement shows Medine GmbH holds 39,218,111 ordinary shares (reported shared voting power) representing 15.5% of the class and Prof. Ugur Sahin, M.D. is reported as beneficial owner of 40,076,320 ordinary shares representing 15.8%.
The percentages are calculated on 252,884,261 ordinary shares outstanding as of March 31, 2026. The filing explains a written arrangement where Prof. Sahin retains voting power over certain shares held by Medine GmbH but not dispositive power; holdings are jointly filed by the two Reporting Persons.
ATHOS KG, AT Impf GmbH and Thomas Maier report beneficial ownership of 101,702,378 Ordinary Shares of BioNTech. This stake represents 40.2% of the class based on 252,884,261 ordinary shares outstanding as of March 31, 2026, per the issuer's disclosure. The holdings are reported on Amendment No. 6 to a Schedule 13G/A and reflect shared voting and dispositive power through ATHOS-related entities.
BioNTech SE Chief Financial Officer Ramon Zapata Gomez received new equity-based compensation. He was granted 15,103 Performance Share Units and 18,879 options, each tied to one ordinary share. The options carry an exercise price of EUR 89.38 and may be settled in ordinary shares, ADSs, or cash.
Both the PSUs and options vest annually in equal installments over four years starting on the first anniversary of the grant. They become exercisable four years after the grant date and are subject to performance and other conditions, including share-price targets relative to the Nasdaq Biotechnology Index.
BioNTech SE reported new equity awards to officer Ryan James Timothy Patrick. On May 12, 2026, he received 10,069 Performance Share Units and an option over 12,586 ordinary shares as compensation, both at a grant price of zero.
The option carries an exercise price of EUR 89.38 and may be settled in ordinary shares, ADSs, or cash at the supervisory board’s election. Both the PSUs and options vest in equal annual installments over four years starting on the first anniversary of the grant date and become exercisable four years after grant, subject to performance and service conditions. PSU performance targets are based on BioNTech’s share price relative to the Nasdaq Biotechnology Index.
BioNTech SE Chief Operating Officer Sierk Poetting reported compensation-related equity grants. He received 10,069 Performance Share Units and 12,586 options, each linked to ordinary shares. These awards were granted at no cash cost to him and are classified as derivative securities.
The options carry an exercise price of EUR 89.38 and may be settled in ordinary shares, ADSs, or cash at the supervisory board’s election. Both the options and PSUs vest annually in equal installments over four years starting on the first anniversary of the grant date and become exercisable four years after the grant date, subject to specified performance and service conditions.
BioNTech SE reported that Chief People Officer Kylie Jimenez received new equity-based compensation. She was granted 8,391 performance share units, each economically equivalent to one ordinary share, and options over 10,488 ordinary shares.
The performance share units and options both vest annually in equal installments over four years starting on the first anniversary of the grant date and become exercisable four years after the grant date, subject to performance-based and other conditions. The option has an exercise price of EUR 89.38 and may be settled in ordinary shares, ADSs, and/or cash at the supervisory board’s election.